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An increasing incidence in disease caused by nontuberculous mycobacteria is being 
reported. We investigated the burden of disease in immunocompetent German 
children in a prospective nationwide study from April 2003 to September 2005. 
Ninety-seven percent of children presented with lymphadenitis; median age was 2.5 
years. Using the capture-recapture method, we estimated a cumulative incidence 




Humans are extensively exposed to natural sources of environmental mycobacteria 
(eg, water, soil). Nontuberculous mycobacterial (NTM) disease develops 
predominantly in immunocompromised individuals but can also present a major 
problem for immunocompetent children.1 Various publications report increasing 
incidence rates of NTM disease in children in developed countries but few nationwide 
studies have been carried out.2–5 Nontuberculous mycobacteria are not included in 
mandatory reporting in Germany and thus, the burden of NTM disease is unknown. 
The Robert Koch Institute and the German Pediatric Surveillance Unit undertook a 
prospective nationwide study to investigate the epidemiology of NTM infections in 
children and determine the burden of NTM disease. Clinical data on NTM cases 
were provided by pediatric hospitals. To detect further cases, laboratories of a 
surveillance network reported NTM isolates. Availability of 2 data sources allowed the 
use of the capture-recapture technique.6 This method has repeatedly been applied in 







All 370 pediatric hospitals and pediatric wards in Germany participate in a notification 
system for conditions that require hospitalization. A total of 480 clinicians monthly 
reported per notification card if they had managed a case of NTM disease. Any 
positive report prompted a detailed questionnaire about clinical presentation and 
demographic characteristics. In case questionnaires were not returned, hospitals 
were contacted by telephone. All microbiologic laboratories serving pediatric 
hospitals and laboratories specialized in detection of mycobacteria (on average 305 
institutions) reported mycobacterial isolates. Laboratories that failed to report were 
contacted by telephone. Details on laboratory diagnosis and demographic 
characteristics were recorded. Clinical cases were defined as immunocompetent 
children<15 years with symptoms consistent with NTM disease, no prior history of 
NTM disease, and admission to hospital between October 2002 and September 
2005. NTM infection had to be laboratory confirmed by positive culture or positive 
PCR plus typical mycobacterial histology. Inclusion criteria for 2-source capture-
recapture analysis were admission to hospital or receipt of sample in the laboratory 
between April 2003 and September 2005, age <15 years and laboratory confirmation 
of NTM by positive culture or positive PCR plus typical mycobacterial histology. 
Because of data protection the collected data allowed no patient identification. To 
identify cases reported by both hospitals and laboratories, matching was performed 
using 10 criteria. Assuming independence of sources, the number of cases missed 
by both sources was estimated.6,9 Data were analyzed with STATA software 
(version 10.0; StataCorp LP, College Station, TX). Information on cases with 
lymphadenitis due to tuberculosis (“TB adenitis”) was obtained by the mandatory 





Participation rates were high for both hospitals (97.2%) and laboratories (95.8%). 
One hundred two cases and 173 isolates fulfilled our case definition. No trend or 
seasonal differences were observed. 
Demographic Characteristics. The majority of cases reported by hospitals belonged 
to the youngest age groups 0 to 4 years (93.1%) with the highest total number of 
cases in the second year of life (30.4%); median age was 2.5 years. In comparison, 
median age of TB adenitis cases was 3 years. Female to male ratio was 1.27. 
Statistical analysis showed no higher probability for female sex to be affected by 
NTM disease. There was no association between geographic location of living (at 
level of German Federal state) and risk to develop NTM disease. Nintyeight percent 
cases originated from Germany and had never lived abroad. 
Clinical Presentation. Ninety-seven percent of children reported by hospitals 
presented with lymphadenitis (Table 1), most frequently with unilateral cervical 
lymphadenitis (75.5%). Of the remaining children, one child had an infected wound, 
one child presented with bronchitis, and for one child no further information was 
provided. Based on our data, we found no evidence for differences in clinical 
manifestation between cases reported by hospitals and those reported by 
laboratories. Clinical symptoms included fever (20.8%), pain (42.7%), and 
development of fistula (16.7%). Stratification of symptoms revealed that fever 
occurred more often in children <4 years (80%) than in children ≥4 years (20%) of 
age. Two children were reported to be BCG vaccinated. Details on clinical 
  
presentation and symptoms of TB adenitis cases were not available. Diagnosis. 
Seventy-two children (82.8%) reported by hospitals showed positive reactions 
following tuberculin skin test (indurations of >5 mm). Forty-nine children (56.3%) had 
indurations of >10 mm with 16 children (19.5%) showing a strong reaction >15 mm. 
Among those 16 children, 2 had received BCG vaccination. Details on skin testing of 
TB adenitis cases were not available. Most often, lymph node material was used for 
establishing the diagnosis (88.7%). Culture isolation was used for NTM isolation 
(88.2%), often combined with histopathologic examination (68.6%). The great 
majority of isolated species were slow-growing mycobacteria, predominantly M. 
avium. Two children had coinfection with M. tuberculosis complex. Their clinical 
presentation did not differ from other cases. 
Treatment. The planned treatment regimen for children with lymphadenitis included 
surgery only (42%), chemotherapy only (17%), a combination of both surgery and 
chemotherapy (39%), and a wait-and-see strategy (2%). However, we have no 
information on the final type of drug treatment. 
Capture-Recapture Analysis. Thirty-seven cases were reported by both the sources, 
133 cases by laboratories only and 43 cases by hospitals only. An estimated 155 
cases were missed by both sources, resulting in a total number of 368 NTM cases 
(95% CI, [255; 514 cases]). Stratification by age and sex confirmed validity of the 
estimated total number. Thus, the estimated cumulative incidence rate of NTM cases 
was 3.3/100000 children (95% CI, [2.3; 4.6]) from April 2003 to September 2005. 
Incidence rate of children <4 years was 11.3 (95% CI, [8.2; 15.6]) and incidence rate 
of children ≥4 years was 1.4 (95% CI [0.9; 1.6]) per 100000. In comparison, the 
cumulative incidence rate of all TB adenitis cases in children was 0.5/100000 (95% 
CI [0.3; 0.6]) from April 2003 to September 2005. Incidence rate of TB adenitis in 
children <4 years was 0.9 (95% CI [0.5;1.4]) and 0.4 (95% CI, [0.3; 0.5]) in children 
≥4 years. Completeness of reporting of hospitals was 22% and completeness 





We investigated the epidemiology of NTM disease in German children with 2 
established and representative prospective nationwide surveillance systems and 
present the first estimate of NTM incidence rate in Germany adjusted for 
underreporting. 
Characteristics of Clinical Cases. The majority of reported children was between 2 
and 4 years old, an age-distribution also reported by other authors.2,3,5 We did not 
find statistical evidence of differences between genders. However, there are reports 
about preponderance of female cases.2–5 In agreement with other publications, the 
majority of children presented with cervical lymphadenitis.4,5 Positive tuberculin 
reactions were observed in 84% of cases. This confirms the diagnosis of NTM 
disease in immunocompetent children.12 The frequency and distribution of 
mycobacterial species varies greatly in different geographic regions of the world. In 
developed countries, M. avium complex is the most common mycobacterial 
species causing disease.1 The results of our study are in line with this. Sensitivity of 
the culture method was reported to be 50% to 80%, even if material is obtained from 
lymph nodes showing NTM-typical histopathology.1 Because of our strict case 
definition for laboratory confirmed cases, we may have precluded some true NTM 
cases due to a lack of positive culture result. These false-negative diagnoses could 
result in an underestimation of total NTM cases.  
  
Estimation of Incidence Rate. Traditional approaches to analyze surveillance data do 
not take into account the number of cases missed by sources. Therefore, estimates 
of disease burden are often biased. Using the capture-recapture approach, we 
estimated a cumulative incidence rate of NTM cases of 3.3/100000 children <15 
years between April 2003 and September 2005 (average yearly incidence rate is 
1.3/100000 children). A prospective study in the Netherlands showed an annual 
incidence of children of 0.8/100000, but the complementary Dutch Chirurgie versus 
Medicatie (CHIMED) study suggested a likely higher incidence of 1.2/100000 
children.2 We found that the 2-source model gives a valid estimate. Consequently, 
cases present in both samples are appropriately matched. However, there could be 
false-positive case ascertainment in laboratories because of primary diagnosis of 
NTM in another laboratory. Some degree of positive dependency of sources likely 
exists in our study. Yet, the effect of “capture bias” is considered to be limited 
because reporting laboratories received samples from different hospitals. Our study 
revealed that many NTM patients are not seen in pediatric hospitals. This finding 
indicates that NTM cases—particularly older age-groups—are also treated in surgical 
or otolaryngologic units or by general practitioners. We assume that clinicians in 
pediatric hospitals are more likely to send samples from NTM cases to laboratories 
for further analysis than clinicians in other hospitals. The CHIMED study has also 
shown that inclusion of specialists like ear, nose, throat physicians, and oral-





Acknowledging potential limitations of the capture-recapture model, our study defines 
the burden of NTM disease in immunocompetent children in Germany. Assuming 
similarity of all cases reported, adenitis in children <4 years is 13 times more likely 
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Table 1. Clinical Characteristics of Cases With NTM Disease Reported by Pediatric 
Hospitals. 
 
 
 
*Temperature >38.5°C. 
